Clinical effect of combination therapy of drug and external shortwave treatment on type IIIB prostatitis

Abstract

Objective To investigate the clinical effect of Xipayimaizibizi and external shortwave treatment on type ⅢB prostatitis. Methods According to the score of NIH-CPSI and prostate fluid examination, 150 patients with type ⅢB prostatitis were selected and randomly divided into the single treatment groups (Xipayimaizibizi or external shortwave) and the combined treatment group (Xipayimaizibizi combined with external shortwave), 50 patients in each group.Four weeks after treatment, the pre-and post-treatment scores on NIH-CPSI pain symptoms, maximal urinary flow rate, average urinary flow rate and the curative effect of each group were compared. Results The symptoms of type ⅢB prostatitis had all improved obviously in three groups. After treatment, the NIH-CPSI score in each group was obviously lower than before. The total effective rate and curative rate of the combined treatment group were 94.00% and 47.00%, which was significantly higher than that in the Xipayimaizibizi group (72.00% and 26.00%) and external shortwave group (68.00% and 20.00%). After treatment, the maximum flow rate and average flow rate were higher than before in three groups. The maximum flow rate and average flow rate in the combined treatment group were obviously higher than in the single treatment group with a significant difference(P<0.05). Three groups had no obvious adverse reactions. Conclusions The combined treatment of Xipayimaizibizi with external shortwave can more significantly improve the symptoms of patients with type ⅢB prostatitis than the separate treatment. In addition to safety and reliability, the clinical application also has the advantage of high cure rate. Key words: Prostatitis; Short-Wave Therapy